IUC26682-89

Abstract Code: IUC26682-89   Efficacy and tolerability of immune checkpoint inhibitors in older versus younger patients with metastatic renal cell carcinoma: a real-world Asian cohort Kanesvaran 1, H.S. Tan 1, J.W.K. Chan 1, W.C. Tan 1, D.J.M. Ang 1, J.J.X. Tan...

IUC26678-94

Abstract Code: IUC26678-94   Impact of Metastatic Patterns on First-Line Therapy in mRCC: Meet-URO 33 Peretto 1, S.E. Rebuzzi 2, E. Verzoni 3, S. Buti 4, M. Di Napoli 5, C. Lolli 6, M. Fanelli 7, C. Masini 8, P.A. Zucali 9, A. Mennitto 10, M. Sorarù 11, R....

IUC26672-88

Abstract Code: IUC26672-88   Treatment beyond progression in primary refractory mRCC during 1L systemic therapy (Meet-Uro 33) Aspden 1, D. Bimbatti 2, A. Dalla Volta 3, G. Roviello 4, R. Iacovelli 5, G. Bozza 6, M.G. Vitale 7, E. Fantinel 8, A. Guida 9, F.M....

IUC26671-87

Abstract Code: IUC26671-87   Adjuvant Pembrolizumab in RCC: Real world experience in Northern Ireland 2022-2026 Buchanan 1, G. Clements 1, C. Forde 1, A. Clayton 1 (1) Northern Ireland cancer centre, Belfast – United Kingdom   Objective: Adjuvant...

IUC26666-91

Abstract Code: IUC26666-91   Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC) Winayak 1, X. Li 1, N.J. Salgia 2,...
error: Content is protected !!